000169356 001__ 169356
000169356 005__ 20260225105429.0
000169356 0247_ $$2doi$$a10.1080/09546634.2017.1296927
000169356 0248_ $$2sideral$$a101922
000169356 037__ $$aART-2017-101922
000169356 041__ $$aeng
000169356 100__ $$0(orcid)0000-0001-8789-6783$$aAra-Martín, Mariano$$uUniversidad de Zaragoza
000169356 245__ $$aImpact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study
000169356 260__ $$c2017
000169356 5203_ $$aPurpose: This study was conducted to examine the relationship between loss of clinical response to anti-tumor necrosis factor (TNF) therapy and the production of anti-drug antibodies (ADAs) and the potential effects of biologic immunogenicity.
Materials and methods: This observational, non-interventional, cross-sectional study included patients with moderate-to-severe plaque psoriasis and secondary failure of adalimumab, etanercept and infliximab who were seen in the clinical practice setting. Clinical data and blood samples were collected after patient enrollment at the time that next doses of anti-TNF therapy were scheduled. ADA and serum drug concentrations were detected at a central reference laboratory using ELISA.
Results: Among 137 enrolled patients, ADA were identified in 31/65 (48%), 0/47 and 8/19 (42%) of patients treated with adalimumab, etanercept and infliximab, respectively. The presence of ADA was associated with a slightly worse clinical response in adalimumab-treated patients (Physician Global Assessment score: 3.7 vs. 3.2, ADA-positive vs. ADA-negative patients [p < .05]; correlation between serum ADA titer and body surface area: r = .292 [p = .019]). Concomitant DMARDs were not associated with anti-TNF immunogenicity in any treatment group.
Conclusions: Additional evidence is needed from studies of anti-TNF therapy in psoriasis for clinicians to gain a better understanding of the impact of immunogenicity on clinical response.
000169356 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000169356 590__ $$a2.144$$b2017
000169356 591__ $$aDERMATOLOGY$$b25 / 63 = 0.397$$c2017$$dQ2$$eT2
000169356 592__ $$a1.022$$b2017
000169356 593__ $$aDermatology$$c2017$$dQ1
000169356 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000169356 700__ $$aHerranz Pinto, Pedro
000169356 700__ $$aPascual-Salcedo, Dora
000169356 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología
000169356 773__ $$g28, 7 (2017), 606-612$$pJ. derm. treat.$$tJOURNAL OF DERMATOLOGICAL TREATMENT$$x0954-6634
000169356 8564_ $$s1052004$$uhttps://zaguan.unizar.es/record/169356/files/texto_completo.pdf$$yVersión publicada
000169356 8564_ $$s1136032$$uhttps://zaguan.unizar.es/record/169356/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000169356 909CO $$ooai:zaguan.unizar.es:169356$$particulos$$pdriver
000169356 951__ $$a2026-02-24-14:47:26
000169356 980__ $$aARTICLE